Abstract. In search for novel markers for breast cancer, we aimed to identify and validate novel serum protein profiles specific for breast cancer, and assess the influence of clinical (subjects age) and pre-analytical (sample storage duration) variables on the constructed classifiers. To this end, sera of breast cancer patients (n=152) and healthy controls (n=129), randomly divided into a training and test set, were analysed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). In the training set, 14 peak clusters were found to differ significantly in expression between cases and controls. None of the peak clusters were influenced by subjects age and sample storage duration. Ten peak clusters were also found significantly discriminative in the test set. Peak clusters were structurally identified as C3a des-arginine anaphylatoxin, (tentative) inter-·-trypsin inhibitor heavy chain 4 fragments and a fibrinogen fragment. Logistic regression analyses on the training set yielded a classification model with a moderate performance on the test set, corresponding to those reported in previously performed validation studies. Most likely originating from the highly heterogeneous nature of breast cancer, selection of breast cancer subgroups for comparison with healthy controls is expected to improve results of future diagnostic SELDI-TOF MS studies.
Introduction
The American Cancer Society has estimated that breast cancer will be the most commonly diagnosed cancer among women in the USA in 2008, as it is expected to account for 26% of all new cancer cases among women (1) . Following lung cancer, breast cancer currently is the second leading cause of cancer deaths in women (1) . As the 5-year survival rate decreases from 98% for localised disease to 26% for distant stage disease (2) , early detection is of paramount importance in reducing breast cancer related mortality. The diagnosis of breast cancer is, however, hampered by a lack of adequate detection methods, resulting in detection of only 63% of breast cancers at an early stage (1) . Although mammography currently is the most widely applied imaging test today, its predictive value is lower in women with dense breast tissue and smaller lesions. Moreover, no molecular markers are recommended for the (early) detection of breast cancer hitherto. Currently used serum tumour markers in breast cancer, e.g., Cancer Antigen 15.3, lack adequate sensitivity and specificity to be applicable in early detection, and are therefore approved by the FDA only for monitoring therapy of advanced breast cancer or recurrence (3) .
The application of a single biomarker in the detection of breast cancer may, however, not be feasible, as a single marker is unlikely to cover the high heterogeneity of breast cancer. Instead, a panel of markers is expected to better reflect breast cancer complexity, yielding improved sensitivity and specificity. With cancer being, for a large part, a genetic disease, researchers initially searched for biomarkers by employing genomic and transcriptomic approaches. Although this has greatly expanded our insight into the genetic basis of cancer, it is currently understood that the functional 'endunits' of the genome, the proteins, cannot be predicted by genetic and transcriptomic data alone. Due to amongst other post-transcriptional mRNA modifications (e.g., alternative splicing) and post-translational protein modifications, one gene can encode multiple proteins, reflecting both the intrinsic genetic programme of the cell and the impact of its immediate environment (4) . As such, the proteome provides a more realistic and detailed view of the biological status, offering a richer source of potential biomarkers.
One of the techniques currently applied in proteomics research of breast cancer is surface-enhanced laser desorption/ ionisation time-of-flight mass spectrometry (SELDI-TOF MS). Until now, eleven studies have been published in which the SELDI-TOF MS platform was applied with varying success in the identification and validation of serum markers for diagnosis (5) (6) (7) (8) (9) (10) (11) (12) , prognosis (13) , or monitoring of therapyefficacy (14) or -toxicity (15) in breast cancer. However, issues have been raised concerning the robustness and validity of alleged markers discovered by SELDI-TOF MS. A potential drawback of analysing high-dimensional proteomic (SELDI-TOF MS) data for disease associated biomarkers is the propensity to discover patterns among variables that are the result of pre-analytical artefacts in a given sample set, rather than of the pathology of interest (16) . Several lines of evidence indicate that pre-analytical variables, e.g., sample collection, processing and storage, can exert profound effects on protein profiles, regardless of true biological variation. In addition, clinical characteristics, such as patients age, could also introduce bias (17) . Despite these concerns, only few studies investigating the serum proteome for discovery of breast cancer specific biomarkers investigate the possible influence of pre-analytical and patient-related variables on the expression of potential biomarkers.
The raised issues on the validity and robustness of alleged biomarkers can, however, also be addressed by validation and structural identification (16) . Nonetheless, thus far, in breast cancer, only two panels of biomarkers discovered by SELDI-TOF MS have been validated by analysis of independent sample sets, resulting in partial (10, 11) or no validation (18) . Moreover, only few biomarkers discovered by SELDI-TOF MS breast cancer research have been structurally identified.
In the current study, we aimed to discover and validate novel serum protein profiles specific for breast cancer. To this end, archival sera of breast cancer patients and healthy controls were analysed using SELDI-TOF MS. Spectral data were merged in one file, after which they were randomly and evenly split into a training and test set. In the training set, we detected 14 discriminating peak clusters, one cluster of which was structurally identified. Furthermore, the relationship between the intensity of the classifier peak clusters and breast cancer status was adjusted for demographic and preanalytical variables (i.e., subjects age and sample storage duration). Finally, the samples in the test set were applied for validation purposes.
Materials and methods
Study population. Archival sera of 152 breast cancer patients (BC) and 129 female healthy controls (HC), collected between January 2003 and July 2005, were analysed on different occasions in our laboratory using standardised analytical procedures. All sera were collected prior to any therapy, with individuals informed consent after approval by the institutional review boards. All sera originate from the Netherlands Cancer Institute serum bank, where they had been collected and stored for 3-50 months at -30˚C according to standard procedures.
Chemicals. All used chemicals were obtained from Sigma, St. Louis, MO, USA, unless stated otherwise.
SELDI-TOF MS protein profiling. Serum protein profiling was performed using the ProteinChip SELDI (PBSIIc) reader (Bio-Rad Labs, Hercules, CA, USA). Various chip chemistries, binding and washing procedures and sample pretreatments were initially evaluated to determine which affinity chemistry and sample pretreatment procedure provided the best serum profiles in terms of number and resolution of proteins. Immobilised metal affinity capture (IMAC30) arrays were selected for further analysis. Samples were analysed in three batches (Batch 1: BC: n=40, HC: n=40; Batch 2: BC: n=43, HC: n=46; Batch 3: BC: n=69, HC: n=43). The samples in Batch 1 were analysed in singlicate, while the samples in Batch 2 and 3 were analysed in duplicate. Throughout the assay, arrays were assembled in a 96-well bioprocessor, which was shaken on a platform shaker at 300 rpm.
Arrays were charged twice with 50 μl of 100 mM nickel sulphate (Merck, Darmstadt, Germany) for 15 min, followed by three rinses with deionised water (Braun, Emmenbrücke, Germany) and two equilibrations with 200 μl phosphatebuffered saline (PBS; 0.01 M) pH 7.4/0.5 M sodium chloride/ 0.1% TritonX-100 (binding buffer; sodium chloride from Merck) for 5 min. Unfractionated serum samples were thawed on ice and denatured by 1:10 dilution in 9 M urea/2% 3-[(3-cholamidopropyl)dimethylammonio-]-1-propanesulfonic acid (CHAPS). Pretreated samples were diluted 1:10 in binding buffer and randomly applied to the arrays. After a 30 min incubation, the arrays were washed twice with binding buffer and twice with PBS pH 7.4/0.5 M sodium chloride for 5 min. Following a quick rinse with deionised water, arrays were air-dried. A 50% sinapinic acid (Bio-Rad Labs) solution in 50% acetonitrile (Biosolve, Valkenswaard, The Netherlands)/0.5% trifluoroacetic acid (Merck) was applied twice (1.0 μl) to the arrays as the matrix. Following airdrying, the arrays were analysed using the ProteinChip SELDI (PBS IIc) reader. As the three batches were analysed on different occasions (with PBS IIc reader maintenance in between), data acquisition was optimised for each sample set separately (data not shown), to obtain similar spectra. For mass accuracy, the instrument was calibrated on each day of measurements with All-in-One peptide standard (Bio-Rad Labs).
Statistics and bioinformatics. Spectra were processed per batch by the ProteinChip Software v3.1 (Bio-Rad Labs). Spectra were baseline subtracted, followed by normalisation to the total ion current. Spectra with normalisation factors >2 or <0.5 were excluded from further analysis. The Biomarker Wizard (BMW) software package was applied for peak detection. BMW settings were optimised for each batch separately (data not shown), to ascertain correct detection of real peaks (instead of peaks that merely represent noise). Peak information was subsequently exported as spreadsheet files, and peak intensities from the duplicate analyses in Batch 2 and 3 were averaged. The three batches were analysed on three separate occasions, a parameter known to influence spectral data (19, 20) . As such, merging peak intensity data of the three batches could lead to spurious results. To this end, first, the intensities of peaks occurring across all three batches were log transformed to obtain normal distributions. Next, the log transformed peak intensities were converted to standard Z-values per batch, by subtracting the mean and dividing by the standard deviation. The log-Z transformed data of the three batches were merged in one file. After this, cases and controls were randomly divided over a training (BC: n=76, HC: n=65) and test (BC: n=76, HC: n=64) set. In the training set, the parametric T-test was applied for the comparison of the mean log-Z transformed peak intensities between cases and controls. Resulting p-values were corrected for multiple testing by the Bonferroni method, by multiplying p-values with the number of peak clusters detected and tested.
To estimate the influence of subjects age and storage duration on the relationship between the 14 discriminating peak clusters and breast cancer status, logistic regression analyses were performed on the training set. We calculated a crude odds ratio per peak cluster, using a univariate model (i.e., by inclusion of only one peak cluster as continuous variable). Next, multivariate odds ratios adjusted for subject's age (categorized according to tertiles: ≤51.3 years, 51.3-61.4 years, >61.4 years), and storage duration (categorized according to tertiles: ≤14.5 months, 14.5-31.7 months, >31.7 months) were calculated. Both parameters were considered confounders if the adjusted odds ratio was 10% different from the crude odds ratio.
To investigate the relationship between a combination of the log-Z transformed peak intensities and the presence of breast cancer, crude odds ratios for each of the peak intensities (as continuous variables) were estimated in a logistic regression model with the inclusion of all peak clusters detected based on forward entry (p<0.05). Again, to investigate whether the relationship between peak intensities and the presence of breast cancer could be explained by the age of the subjects and/or sample storage duration, the odds ratios were adjusted for these parameters.
The classification performance of the logistic regression model was evaluated by estimation of the area under the receiver operating characteristic (ROC) curve (AUC) and accompanying 95% confidence interval. The model was subsequently applied to the test set for validation purposes. All statistical analyses were performed using SPSS statistical software, version 13.0 (SPSS Inc., Chicago, IL, USA).
Peptide purification and identification. Structural identification of potential biomarkers was performed previously (Gast et al, unpublished data) . Briefly, potential markers were purified from serum using anion-exchange chromatographic, size exclusion, and gel-electrophoresis techniques, followed by trypsin digestion. The peptide map of the digest, acquired on the ProteinChip SELDI (PBS IIc) Reader, was investigated with the NCBI database using the ProFound search engine at http://prowl.rockefeller.edu/prowl-cgi/profound.exe. Confirmation of protein identity was provided by sequencing tryptic digest peptides by quadrupole-TOF (Q-TOF) MS (Applied Biosystems/MSD Sciex, Foster City, CA, USA) fitted with a ProteinChip Interface (PCI-1000). Fragment ion spectra were taken to search the SwissProt 44.2 database (Homo Sapiens: 11072 sequences) using the MASCOT search engine at www.matrixscience.com (Matrix Science Ltd., London, UK). Protein identity was further confirmed by immunoassay on ProteinA beads (Gast et al, unpublished data) .
Results
Study population. Patient and sample characteristics are summarized in Table I . The healthy controls were significantly younger than the breast cancer patients at time of sample procurement [Mann-Whitney U test (MWU); p<0.001]. The majority of breast cancer patients had invasive ductal carcinoma (76%) and was diagnosed with Stage 2 (63%) disease. The median sample storage duration was slightly longer for breast cancer sera (median: 26.0 months) than for the healthy control sera (median: 20.1 months) (MWU; p=0.018). Table I . Patient and sample characteristics of the study population. -
SELDI-TOF MS protein profiling.
Representative SELDI-TOF MS spectra are presented in Fig. 1 . Following spectrum pre-processing and normalisation, 73 (BC: n=36; HC: n=37), 89 (BC: n=43; HC: n=46), and 111 samples (BC: n=68; HC: n=43) were left for analysis in Batch 1, 2, and 3, respectively. The Biomarker Wizard detected 57 peak clusters across all three batches. In the training set, 14 peak clusters were found significantly different in expression between breast cancer and control (T-test; Bonferroni corrected p<0.05, Table II ). Except for the m/z 4219 and m/z 11745 peak clusters, intensities were found decreased in breast cancer compared to control (Table II: logistic regression, odds ratio <1). Following correction for subject's age and sample storage duration, the adjusted odds ratios of three peak clusters (m/z 2733, 3965, and 4219) differed by >10% from the crude odds ratios. All three peaks remain, however, Table II . Characteristics of the 14 clusters that differ significantly in expression between breast cancer and healthy control in the training set. 
95% CI, 95% confidence interval; NS, not significant; OR, odds ratio.
a Crude logistic regression analyses, by inclusion of one peak cluster (continuous), b adjusted logistic regression analyses (training set only), by inclusion of one peak cluster (continuous), subject's age (categorical), and sample storage duration (categorical), c Bonferroni corrected p-values.
-----------------------------------------------------------------------------------------------------
significantly related to breast cancer status. Ten of these 14 peak clusters were found significantly different in peak expression between breast cancer and control in the test set as well. Next, multivariate logistic regression analyses were performed on the training set. Following forward entry inclusion of all peak clusters detected spectrum-wide, four peak clusters (m/z 4219, 4309, 5350, and 29183) were incorporated in the model, resulting in a ROC AUC of 0.813 (85% CI: 0.742-0.884) (Table III) . Two peak clusters (m/z 4219 and 4309) were already found significantly different in peak expression between breast cancer and healthy control. Of the four peak clusters included in this model, only m/z 4219 had an adjusted odds ratio that differed >10% from the crude odds ratio. Similar to the univariate analyses, however, after adjustment this peak cluster was even more strongly related to breast cancer status. The multivariate model classified the samples in the training set with a sensitivity and specificity of 74.3 and 71.9%, respectively. Model performance was lower following validation on the test set [ROC AUC: 0.713 (95% CI: 0.626-0.800); sensitivity: 72.6%, specificity: 61.3%].
Peptide purification and identification. One of the 14 peak clusters found significantly different between breast cancer and control was m/z 8940, which we previously identified as complement component 3 precursor by peptide mapping (ProFound; estimated Z-score 1.57, 4% sequence coverage) (Gast et al, unpublished data). Amino acid sequencing of 6 peptides in the tryptic digest by tandem MS on a Q-TOF identified the marker as C3a des-arginine anaphylatoxin (C3a desArg , 61% sequence coverage), a 76 amino acid protein with theoretical mass 8939.46 Da and pI 9.54. This identity was confirmed by an immunoassay, for which ProteinA beads were loaded with a C3a polyclonal antibody (Abcam Ltd., Cambridge, UK) (Gast et al, unpublished data). Fig. 2 depicts the correlation matrix presenting the (absolute) Pearson's correlation coefficients calculated between the peak intensities of the 14 peaks found significantly different in expression between breast cancer and healthy control. To preclude bias by group, all Pearson's correlation analyses were performed in the healthy controls of the total study population. As 11 peak clusters were found highly correlated to each other (Pearson's R>0.63, Fig. 2 ), we hypothesize these clusters to represent multiple fragments of one founder protein. Using data from previous publications, we suggest this founder protein to be inter-·-trypsin inhibitor heavy chain 4 (ITIH4). Eight of the alleged ITIH4 peak clusters had an observed mass corresponding to the theoretical mass of the different ITIH4 fragments described in the literature (Table IV) . The peak clusters at m/z 4219 and 11745 were not correlated to any of the significantly different peak clusters. The m/z 4219 and m/z 5350 peak clusters, selected in the multivariable logistic regression analysis, were previously identified as (putative) fibrinogen fragments by our group. ONCOLOGY REPORTS 22: 205-213, 2009 Table III. Multivariate logistic regression analyses in the training set, by forward entry inclusion of all peak clusters detected, before and after adjustment for subjects age and sample storage duration. 
-----------------------------------------------------------------------------------------------------Multivariate model Multivariate model, adjusted ---------------------------------------------------------------------------Variable OR (95% CI) p-value OR (95% CI) p-value -----------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------- Performance Multivariate model ----------------------------------------------------------------------------------------------------- ROC
3% -----------------------------------------------------------------------------------------------------
AUC, area under the receiver operating characteristic (ROC) curve; 95% CI, 95% confidence interval; OR, odds ratio; ROC, receiver operating characteristics curve.
-----------------------------------------------------------------------------------------------------

Discussion
In the current study, sera of breast cancer patients (n=152) and healthy controls (n=129) were analysed using the SELDI-TOF MS technology. Spectra were divided into a training and test set, and 14 peak clusters were found to differ significantly in peak expression between breast cancer and healthy control in the training set. Ten of these 14 peak Table IV . Stuctural identities of eight alleged ITIH4 peak clusters that significantly differ in expression between breast cancer and healthy control in the training set. 
, inter-·-trypsin inhibitor heavy chain 4; Mr (obs), observed mass-to-charge ratio; Mr (calc), calculated mass from the matched peptide sequence.
-
clusters could also be validated in the test set. We previously identified one peak cluster as C3a desArg , while 12 other peak clusters were tentatively identified as ITIH4 fragments and a fibrinogen fragment, respectively. A classification model was subsequently generated by multivariate logistic regression analysis on the training set. Its performance on the test set was similar to those reported by previously performed independent validation studies (10, 11, 18, 21) . Hence, our splitsample approach yielded reliable estimates of performance. Nonetheless, the diagnostic performances reported thus far are moderate. The identification of a general diagnostic biomarker is, however, seriously challenged by the molecular characteristics of breast cancer, which are highly heterogeneous (22) (23) (24) . As such, selection of breast cancer subgroups for comparison with healthy controls is expected to improve results of future diagnostic SELDI-TOF MS studies.
Complement C3a desArg . We discovered the expression of the serum m/z 8940 C3a desArg peak to be significantly decreased in breast cancer compared to controls in both the training and test set. Complement C3 is the most abundant (1.2 mg/ml) complement protein in serum (25) , supporting the activation of all three pathways of complement activation (the classic, alternative, and lectin pathway) (26, 27) . Produced mainly in the liver and adipocytes, C3a is formed by cleavage of C3 (185 kDa) by C3-convertases into C3b (176 kDa) and C3a (8.9 kDa) (28) . The anaphylatoxin C3a is only short lived in serum as carboxypeptidases cleave the C-terminal arginine residue, creating the more stable, but biologically inactive C3a desArg (8.9 kDa) (27) (28) (29) .
As C3 is a positive acute phase reactant (30) , elevated serum levels of C3 [and hence, C3a (desArg) ] in cancer compared to control are anticipated. Indeed, elevated serum C3 levels have been described in various cancer types, including neuroblastoma (31), lung cancer (32) , and cancer of the digestive tract (33) . Likewise, increased serum C3a desArg levels, determined by SELDI-TOF MS, have been reported in breast (9, 10) , hepatocellular (34) , and colorectal cancer (35, 36) , and chronic lymphoid malignancies (37) . We, on the other hand, observed decreased C3a desArg levels in breast cancer in the current study population, as well as in a subset thereof, which we analysed for validation of the 8.9 kDa marker reported by Li et al (21) . Other studies have described decreased 8.9 kDa peak intensities in breast (7, 38) , and lung cancer (39) . Moreover, Li et al observed decreased SELDI-TOF MS C3a desArg peak intensities in sera of metastatic breast cancer patients (10) . Their finding is corroborated by the decreased serum C3 levels reported in patients with metastatic breast, gastric, and colorectal cancer (33) and brain tumours (31) . Hence, complement activation seems an early event during tumourigenesis. This, however, can not explain the results of the current study, as we included only sera of patients with locally invasive breast cancer.
An other possible explanation for the observed inconsistensies in 8.9 kDa C3a desArg regulation can be the in vitro complement activation, caused by coagulation induced platelet activation (40) . Banks et al (41) reported the intensity of an IMAC3 m/z 8939 peak (not structurally identified though) to significantly increase with prolonged coagulation times.
Coagulation time is, however, an unlikely confounder, as studies generally apply standardised collection protocols for both cancer and control samples. C3a desArg levels can also be affected by sample storage time. In a previous study, we found the m/z 8939 C3a desArg peak intensity positively correlated to sample storage time during the first three years of storage, after which intensities remained stable. Although in the current study, the breast cancer sera were stored for a slightly longer period than the control sera, storage time of both sample groups was less than three years. Moreover, as the m/z 8939 peak performance was not influenced by adjustment for sample storage duration, this parameter is unlikely to have confounded results of the current study.
ITIH4 fragments.
Of the 14 peaks we found significantly different in expression between breast cancer and healthy controls, 11 were identified as putative ITIH4 fragments. The peak intensities of all putative ITIH4 fragments were decreased in breast cancer compared to control. ITIH4, a 120 kDa plasma glycoprotein expressed mainly in the liver, acts as a positive acute phase reactant and is extensively proteolytically processed (42) . Plasma kallikrein readily cleaves ITIH4 into an N-terminal 85 kDa and C-terminal 35 kDa fragment, after which the 85 kDa fragment is further cleaved into an N-terminal 57 kDa and a putative 28 kDa fragment. The latter fragment has not been detected in its entirety hitherto, as it is rapidly cleaved into subsequent smaller fragments (42) . Changes in the abundance of different fragments have been found associated with various types of cancer (e.g., prostate, breast, ovarian, colorectal and pancreatic cancer) (42) (43) (44) , indicating cancer-type specific proteolytic processing of ITIH4. Three of the 11 putative ITIH4 fragments (i.e., m/z 2733, m/z 3282, and m/z 4292) have been reported as potential markers for breast cancer (42) . Unlike our results, however, this study found increased peak intensities of the three fragments in cancer compared to control (42) .
The m/z 4292 ITIH4 fragment has also been described by Li et al (9, 10) . They initially observed a 4.3 kDa ITIH4 fragment to be downregulated in breast cancer (9), but found this peak upregulated upon validation (10) . In their original discovery study, the cancer sera were collected during a (non-specified) longer time interval than the control sera, whereas in the validation study, sera of both cases and controls were collected within a two-year time interval. Combined with the postulated instability of the ITIH4 fragment (causing further truncation during prolonged storage), this could indeed explain their discrepant results. Nonetheless, following analysis of prospectively collected sera, Mathelin et al (11) also observed a decreased expression of the m/z 4292 ITIH4 peak intensity in breast cancer. This decrease was also observed following analysis of a subset of the current study population for validation of the markers reported by Li et al (21) . However, the decrease of m/z 4292 observed in the breast cancer cases of the current study could not be explained by the difference in storage duration between the cancer and control sera, as correction for this parameter by logistic regression analyses did not affect the performance of the m/z 4292 peak. In addition, evidence for the alleged 4.3 kDa ITIH4 fragment instability is only limited. Peak intensities of ONCOLOGY REPORTS 22: 205-213, 2009 this fragment were found to be both increased (45) and decreased by different (pre-) analytical parameters (42, 43) , though the fragmentation pattern was not altered (42, 43) . Perhaps the discrepant results of the various studies are caused by differences between the patient populations investigated in the various studies.
Other markers. Of the 14 peak clusters found significantly different in expression between breast cancer and healthy controls, both m/z 4219 and m/z 11745 were not correlated to any of the other peak clusters. While we previously identified m/z 4219 as a putative fibrinogen fragment, the identity of m/z 11745 peak is yet unknown. The m/z 5350 peak cluster, included in the logistic regression model, was identified earlier as a fibrinogen fragment as well (i.e., fibrinogen ·-E fragment FGA 576-625 ). The multivariate classification model furthermore designated the m/z 28183 peak cluster as a potential marker, in combination with m/z 4219, 4309, and 5350. Although peak intensities of both m/z 5350 and m/z 28183 were not significantly different in expression between breast cancer and healthy control, combination with other markers evidently improved their diagnostic performance. The m/z 5350 peak cluster, though not structurally identified, has been reported earlier as significantly increased in sera of patients with lung cancer (39) and hypopharyngeal squamous cell carcinoma (46) . Based on the observed mass, we hypothesise the m/z 28183 peak cluster to represent apolipoprotein A-I. This protein was previously identified by our group as a potential marker for colorectal cancer by serum SELDI-TOF MS analyses (47) . Synthesised both in the liver and small intestine, apolipoprotein A-I constitutes the major component of high-density lipoproteins (48) . It is a negative acute phase reactant (49) , explaining the decreased expression we observed in cancer vs. healthy control (Table II , crude odds ratio <1). Its decreased expression in cancer is confirmed by other studies investigating breast (48) , ovarian (50), colorectal (47) , and hepatocellular cancer (51) .
In conclusion, using SELDI-TOF MS, we discovered and validated 10 peak clusters that significantly differ in expression between sera of breast cancer patients and healthy controls. These peak clusters were structurally identified as the high abundant C3a desArg anaphylatoxin, and putative ITIH4 and fibrinogen fragments. Logistic regression analyses in the training set yielded a classification model with a performance comparable to those reported in previously performed independent validation studies. As these moderate performances most likely originate from the highly heterogeneous nature of breast cancer, selection of breast cancer subgroups for comparison with healthy controls is expected to improve results of future diagnostic SELDI-TOF MS studies.
